| Carcinoma breast stage IV
Abraxane vs Perjeta
Side-by-side clinical, coverage, and cost comparison for carcinoma breast stage iv.Deep comparison between: Abraxane vs Perjeta with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsPerjeta has a higher rate of injection site reactions vs Abraxane based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Perjeta but not Abraxane, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Abraxane
Perjeta
At A Glance
IV infusion
Weekly to every 3 weeks
Microtubule inhibitor
IV infusion
Every 3 weeks
HER2/neu receptor antagonist
Indications
- Carcinoma breast stage IV
- Non-Small Cell Lung Carcinoma
- Adenocarcinoma of pancreas
- Carcinoma breast stage IV
- Locally Advanced Breast Carcinoma
- Inflammatory Breast Carcinoma
- Early Stage HER2-Positive Breast Carcinoma
Dosing
Carcinoma breast stage IV 260 mg/m2 IV over 30 minutes every 3 weeks.
Non-Small Cell Lung Carcinoma 100 mg/m2 IV over 30 minutes on Days 1, 8, and 15 of each 21-day cycle; administer carboplatin on Day 1 of each 21-day cycle immediately after ABRAXANE.
Adenocarcinoma of pancreas 125 mg/m2 IV over 30-40 minutes on Days 1, 8, and 15 of each 28-day cycle; administer gemcitabine on Days 1, 8, and 15 of each 28-day cycle immediately after ABRAXANE.
Carcinoma breast stage IV Initial 840 mg IV over 60 min, then 420 mg IV every 3 weeks; administered with trastuzumab and docetaxel.
Locally Advanced Breast Carcinoma, Inflammatory Breast Carcinoma, Early Stage HER2-Positive Breast Carcinoma Initial 840 mg IV, then 420 mg IV every 3 weeks with trastuzumab and chemotherapy; neoadjuvant: 3-6 preoperative cycles followed by postoperative continuation to complete 1 year; adjuvant: 1 year total (up to 18 cycles), starting Day 1 of first taxane-containing cycle.
Contraindications
- Baseline neutrophil count below 1500 cells/mm3
- History of severe hypersensitivity reaction to ABRAXANE
- Known hypersensitivity to pertuzumab or any of its excipients
Adverse Reactions
Most common (>=20%) Alopecia, neutropenia, sensory/peripheral neuropathy, abnormal ECG, fatigue/asthenia, myalgia/arthralgia, AST elevation, alkaline phosphatase elevation, anemia, nausea, infections, diarrhea, thrombocytopenia, peripheral edema, pyrexia, vomiting, decreased appetite, rash, dehydration
Serious Anemia, pneumonia, pyrexia, dehydration, vomiting
Postmarketing Severe hypersensitivity reactions, congestive heart failure, left ventricular dysfunction, atrioventricular block, pneumonitis, interstitial pneumonia, pulmonary embolism, cranial nerve palsies, vocal cord paresis, autonomic neuropathy, cystoid macular edema, hepatic necrosis, intestinal obstruction, intestinal perforation, pancreatitis, ischemic colitis, tumor lysis syndrome, Stevens-Johnson syndrome, toxic epidermal necrolysis
Most common (>30%) diarrhea, alopecia, neutropenia, nausea, fatigue, rash, peripheral neuropathy
Serious neutropenia, febrile neutropenia, leukopenia, diarrhea, peripheral neuropathy, anemia, asthenia, fatigue
Pharmacology
ABRAXANE is a microtubule inhibitor that promotes assembly and stabilization of microtubules from tubulin dimers, inhibiting the normal dynamic reorganization of the microtubule network essential for vital interphase and mitotic cellular functions.
Pertuzumab is a HER2/neu receptor antagonist that blocks ligand-dependent heterodimerization of HER2 with other HER family members (EGFR, HER3, HER4), inhibiting MAP kinase and PI3K signaling pathways to cause cell growth arrest and apoptosis; it also mediates antibody-dependent cell-mediated cytotoxicity (ADCC).
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Abraxane
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (0/12)
Perjeta
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Abraxane
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Perjeta
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Abraxane
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (0/3)
Perjeta
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Abraxane.
No savings programs available for Perjeta.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AbraxaneView full Abraxane profile
PerjetaView full Perjeta profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.